08-29-05



PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to res

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

		· dimede it diepie/e a_taile emis de ille i ilaniser
	Application Number	10/825,911
	Filing Date	April 16, 2004
	First Named Inventor	Xinli LIN
ling)	Art Unit	1652
	Examiner Name	I. Chowdhury
6+6 References	Attorney Docket Number	544112000200

ENCLOSURES (Check all that apply)						
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC				
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendment/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)				
After Final	Petition to Convert to a Provisional Application	Proprietary Information				
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter				
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please Identify below):				
Express Abandonment Request	Request for Refund	PTO/SB/08a/b + copy (2 pages) Reference (6)				
x Information Disclosure Statement (3 pages)	CD, Number of CD(s)	Return Receipt Postcard				
Certified Copy of Priority Document(s)	Landscape Table on CD					
Reply to Missing Parts/ Incomplete Application	Remarks					
Reply to Missing Parts under 37 CFR 1.52 or 1.53						
	,					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name MORRISON & FOE	MORRISON & FOERSTER LLP (Customer No. 25226)					
Signature	Siz					
Printed name Jie Zhou						
Date August 25, 2005	Reg. No.	52,395				

	ndence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 544973848 US, Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date
Dated: August 25, 2005	Signature: Augua Maloz (Georgina Matos)

22313-1450, on the date shown below. Dated: August 25, 2005 Signature:

ereby certify that this correspondence is being deposited with the U.S. Postal ervice as Express Mail, Airbill No. EV 544973848 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

Patent Docket No. 544112000200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Xinli LIN

Serial No.: 10/825,911

Filing Date: April 16, 2004

METHODS FOR PRODUCTION OF

RECOMBINANT UROKINASE

Examiner: I. Chowdhury

Group Art Unit: 1652

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

Pursuant to 37 C.F.R. § 1.704(d), I hereby certify that items numbered 1 and 4-7 contained in this Supplemental Information Disclosure Statement were first cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this Supplemental Information Disclosure Statement.

This Supplemental Information Disclosure Statement is submitted: With the application; accordingly, no fee or separate requirements are required. Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided. \boxtimes Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided. After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance. A fee is required. A check in the amount of is enclosed. A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate. П A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due. П After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed. A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.) Applicant would appreciate the Examiner initialing and returning the Form

PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 544112000200.

Dated: August 25, 2005

Respectfully submitted,

lie Zhou

Registration No.: 52,395

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304-1018

(650) 813-5922



Cubatituda for form 4440/DTO		Complete if Known				
Substitute for form 1449/PTO		Application Number	10/825,911			
INFORMATION DISCLOSURE				Filing Date	April 16, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Xinli LIN	
OTATEMENT BY ATTEMANT		Art Unit	1652			
	(Use as many	y she ets as	necess ary)	Examiner Name	I. Chowdhury	
Sheet	1	of	1	Attorney Docket Number	544112000200	

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.3	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	1.	US-4,106,992	08-15-1978	Vairel et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	2.	WO-2005/058243-A2	06-30-2005	Proteomtech Inc.		
	3.	WO-2005/058930-A2	06-30-2005	Proteomtech Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	4.	Fahey, E.M. et al. (2000). "Refolding and Purification of a Urokinase Plasminogen Activator Fragment by Chromatography," <i>Journal of Chromatography B</i> 737:225-235.		
	5.	Hua, Z-C. et al. (1996). "Renaturation of Recombinant Human Pro-Urokinase Expressed in Escherichia coli," Biochemical and Biophysical Research Communications 220:131-136.		
	6.	Hui, Z. et al. (2001). "In Vitro Renaturation of Recombinant Human Pro-Urokinase Expressed in Escherichia coli," Chinese Medical Journal 114(2):186-190.		
	7.	International Search Report mailed on July 25, 2005 for PCT Application No. PCT/US04/11792 filed April 16, 2004, 4 pages.		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.